Explore the latest pharmaceutical research, new drug developments, and FDA approvals. Stay informed on the therapies transforming disease management, from cancer treatments to chronic disease medications.
In a significant leap forward for medtech innovation, ARS Pharmaceuticals has secured FDA approval for Neffy 1 mg, the first needle-free epinephrine nasal spray designed
Key Takeaways: FDA approvals in 2025 have highlighted therapies addressing rare diseases, oncology, and chronic conditions. Innovative drugs with new mechanisms of action are transforming
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
Quick Summary •Market Reaction: Biotech stocks saw modest gains following Trump’s 2024 election victory, reflecting optimism about regulatory leniency and M&A activity. •Key Appointments: Speculation
Quick Summary Clinical Data: Viking Therapeutics reported positive weight-loss results from trials of its oral obesity drug candidate. Market Reaction: Despite the positive clinical data,
Quick Summary Drug Development: Novo Nordisk plans to expand its obesity drug’s applications to treat metabolic-associated steatohepatitis (MASH). Clinical Findings: New trials indicate the drug’s
Quick Summary Election Outcome: Donald Trump’s recent victory is anticipated to bring major changes to U.S. healthcare and biotech regulation. Key Players: Trump has suggested
Quick Summary Election Outcome: The 2024 election could reshape U.S. biotech regulation, with different regulatory priorities depending on the administration. Kamala Harris’s Approach: Harris focuses
Quick Summary Issue: Asian pharmaceutical suppliers are producing and exporting cheaper versions of semaglutide, the active ingredient in Ozempic and Wegovy. Key Players: Incepta Pharmaceuticals
Quick Summary Funding: Inventiva, a French biotech company, has raised €348 million in one of France’s largest biotech fundings. Focus: Advancing clinical trials for NASH
